Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival
Stock Information for Cardiff Oncology Inc.
Loading
Please wait while we load your information from QuoteMedia.